Acquired myasthenia gravis (MG) is a disorder of neuromuscular transmission, resulting from binding of autoantibodies to components of the neuromuscular junction, most commonly the acetylcholine receptor (AChR). The incidence ranges from 0.3 to 2.8 per 100,000,1 and it is estimated to affect more than 700,000 people worldwide. The increasing use of immunomodulating therapies has been a major factor in improving the prognosis for patients with MG in recent years.2 The various treatment options must be weighed in the context of individual patient factors.
top of page
bottom of page